With the clinical trial community gathering for DIA 2015, eClinical tech vendors have been rolling out releases about their new tools, hires and deals. Here we round up a batch of notable news, including a new hire at Clinical Ink, deals for DocuSign and a visit to the FDA by Nextrials.
 |
| Clinical Ink Chief Data Officer Jonathan Andrus |
First, to Clinical Ink. The electronic source data specialist marked DIA by unveiling former BioClinica VP Jonathan Andrus as its chief data officer. In the role, Andrus will take responsibility for helping Clinical Ink's clients to make better use of their electronic source data, patient reported outcomes and trial participant engagement reports, resources the company thinks can make trials more efficient and of a higher quality. Andrus joins the company after a 13-year stint at BioClinica.
DocuSign went into DIA armed with figures showing that 14 of the top 15 pharma companies and 9 of the top 10 CROs now use its service. The digital signature player lists Allergan ($AGN), AstraZeneca ($AZN) and Bayer among the companies that have standardized their operations on its platform. In AstraZeneca's case, the selection of DocuSign as its electronic signature service was part of a push to have everyone in the organization use the same IT system for certain tasks.
Nextrials arrived at the conference trumpeting the news of a recent meeting with the FDA, at which the electronic data capture (EDC) vendor discussed the integration of its product with electronic health records (EHRs). The FDA reportedly asked Nextrials to give the demonstration as part of its attempts to better understand how such integrations could improve data collection and safety monitoring. Nextrials has furthered the field by creating an EHR-integration tool for its EDC platform.
Finally, Quintiles ($Q) used the event to publicize an update to its risk-based monitoring offering. The new addition brings statistical monitoring and predictive analytics capabilities to the platform, features the CRO thinks will make it possible to forecast trial site performance and safety issues.
- read the Clinical Ink release
- here's DocuSign's news
- check out Nextrials' statement
- and Quintiles' post